Vivo Capital LLC held its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) during the second quarter, according to its most recent filing with the SEC. The fund owned 77,373 shares of the biopharmaceutical company’s stock at the end of the second quarter. Revance Therapeutics accounts for approximately 0.5% of Vivo Capital LLC’s investment portfolio, making the stock its 24th largest position. Vivo Capital LLC’s holdings in Revance Therapeutics were worth $2,043,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in RVNC. American International Group Inc. raised its stake in shares of Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 834 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Revance Therapeutics by 5.9% in the first quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 1,524 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Revance Therapeutics by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 33,722 shares of the biopharmaceutical company’s stock valued at $698,000 after buying an additional 1,650 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Revance Therapeutics by 29.5% in the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,651 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Revance Therapeutics by 6.8% in the first quarter. Swiss National Bank now owns 32,850 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 2,100 shares during the last quarter. 87.29% of the stock is currently owned by institutional investors.

Revance Therapeutics, Inc. (RVNC) opened at 23.35 on Friday. The company’s 50 day moving average price is $24.38 and its 200 day moving average price is $21.91. Revance Therapeutics, Inc. has a 52-week low of $12.35 and a 52-week high of $28.30. The company’s market cap is $719.62 million.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.93) by $0.03. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.05 million. Revance Therapeutics had a negative return on equity of 55.21% and a negative net margin of 32,936.67%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.88) earnings per share. Equities research analysts anticipate that Revance Therapeutics, Inc. will post ($3.75) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/13/vivo-capital-llc-holds-position-in-revance-therapeutics-inc-rvnc.html.

Several brokerages have recently weighed in on RVNC. Zacks Investment Research lowered Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. BidaskClub downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Cantor Fitzgerald assumed coverage on Revance Therapeutics in a research report on Thursday, July 20th. They set an “overweight” rating and a $50.00 target price for the company. Aegis restated a “buy” rating and set a $36.00 target price (up previously from $28.00) on shares of Revance Therapeutics in a research report on Friday, May 19th. Finally, ValuEngine upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. Revance Therapeutics presently has an average rating of “Hold” and a consensus price target of $34.75.

In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 1,793 shares of the company’s stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $20.20, for a total transaction of $36,218.60. Following the completion of the sale, the chief financial officer now directly owns 36,566 shares in the company, valued at $738,633.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO L Daniel Browne sold 12,287 shares of the company’s stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $20.20, for a total value of $248,197.40. Following the sale, the chief executive officer now owns 183,932 shares of the company’s stock, valued at $3,715,426.40. The disclosure for this sale can be found here. Insiders have sold 33,793 shares of company stock worth $685,576 in the last three months. 18.86% of the stock is currently owned by company insiders.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.